179 related articles for article (PubMed ID: 2126024)
1. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
2. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma].
Kurose T; Hando T; Shiota A
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):35-41. PubMed ID: 7844451
[TBL] [Abstract][Full Text] [Related]
4. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause.
Imai A; Sugiyama M; Furui T; Tamaya T
J Obstet Gynaecol; 2003 Sep; 23(5):518-20. PubMed ID: 12963511
[TBL] [Abstract][Full Text] [Related]
5. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyoma: treatment with LHRH agonist.
Maheux R; Lemay A
Prog Clin Biol Res; 1986; 225():297-311. PubMed ID: 3097669
[No Abstract] [Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
8. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
9. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
10. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
12. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
13. Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin-releasing hormone.
Sakamoto S; Mitamura T; Iwasawa M; Kitsunai H; Shindou K; Yagishita Y; Zhou YF; Sassa S
In Vivo; 1998; 12(3):333-7. PubMed ID: 9706480
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
15. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
Hilário SG; Bozzini N; Borsari R; Baracat EC
Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
[TBL] [Abstract][Full Text] [Related]
16. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
Shaw RW; Matta W
Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
[TBL] [Abstract][Full Text] [Related]
17. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
[TBL] [Abstract][Full Text] [Related]
18. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
19. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
Huhtaniemi I; Venho P; Jacobi G; Rannikko S
J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
[TBL] [Abstract][Full Text] [Related]
20. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors.
Kreuser ED; Hetzel WD; Hautmann R; Pfeiffer EF
Horm Metab Res; 1990 Sep; 22(9):494-8. PubMed ID: 1701752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]